UBE2N and ovarian carcinoma: Kaplan-Meier survival curves revealed that ovarian cancer patients with UBC13 low-expression had significantly poorer progression-free survival (PFS, P = 0.036) and overall survival (OS, P = 0.029) than those with high UBC13 expression (Fig. 2b).